HC Wainwright Trims Nyxoah (NASDAQ:NYXH) Target Price to $17.00

Nyxoah (NASDAQ:NYXH) had its price objective lowered by analysts at HC Wainwright from $18.00 to $17.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 81.43% from the stock’s current price.

NYXH has been the topic of several other research reports. Oppenheimer reduced their price target on shares of Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Cantor Fitzgerald reduced their price target on shares of Nyxoah from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Finally, Stifel Nicolaus reduced their price target on shares of Nyxoah from $27.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, June 24th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $17.00.

Nyxoah Stock Performance

Nyxoah stock traded down $0.19 during trading hours on Friday, hitting $9.37. The company had a trading volume of 24,268 shares, compared to its average volume of 52,768. The firm has a market cap of $233.69 million, a PE ratio of -5.55 and a beta of 1.45. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.47 and a quick ratio of 5.16. Nyxoah has a one year low of $4.00 and a one year high of $20.00. The firm has a 50-day moving average of $8.38 and a 200 day moving average of $9.06.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Tuesday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.01). The business had revenue of $0.83 million for the quarter, compared to analyst estimates of $1.93 million. Nyxoah had a negative return on equity of 42.00% and a negative net margin of 908.32%. On average, sell-side analysts expect that Nyxoah will post -1.91 earnings per share for the current year.

Hedge Funds Weigh In On Nyxoah

Large investors have recently modified their holdings of the business. CVI Holdings LLC bought a new position in shares of Nyxoah during the second quarter valued at $1,292,000. Ikarian Capital LLC bought a new stake in Nyxoah in the first quarter valued at $684,000. Finally, Iron Triangle Partners LP bought a new stake in Nyxoah in the first quarter valued at $3,413,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.